Sort Through Options for Managing Heart Failure

December 2025

You’ll hear buzz about finerenone (Kerendia) and the GLP-1 receptor agonists semaglutide and tirzepatide for certain types of heart failure.

There’s some evidence for these in heart failure with mildly reduced ejection fraction (HFmrEF) or preserved EF (HFpEF)...with an EF greater than 40% or 50%, respectively.

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) previously used for CKD...now approved for HF with EF ≥40%.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote